natgillin/translations-raw huggingface dataset:
The complete SmPC of Quadramet is provided as a separate document in the product package, with the objective to provide healthcare professionals with other additional scientific and practical information about the administration and use of this radiopharmaceutical.
Cjeloviti Sažetak opisa svojstava lijeka Quadramet priložen je kao zaseban dokument unutar pakovanja, s ciljem da zdravstvenim djelatnicima pruži dodatne znanstvene i praktične podatke o primjeni i uporabi ovog radiofarmaceutika.
The complete SmPC of VIZAMYL is provided as a separate document in the product package, with the objective to provide healthcare professionals with other additional scientific and practical information about the administration and use of this radiopharmaceutical.
Kompletan SmPC VIZAMYL-a isporučuje se kao odvojeni dokument u pakiranju lijeka, s ciljem pružanja dodatnih znanstvenih i praktičnih informacija o primjeni i uporabi ovog radiofarmaceutika zdravstvenim djelatnicima.
The complete SmPC of Xofigo is provided as a tear-off section at the end of the printed leaflet in the product package, with the objective to provide healthcare professionals with other additional scientific and practical information about the administration and use of this radiopharmaceutical.
Potpuni Sažetak opisa svojstava lijeka za Xofigo dostupan je kao dio koji se može otkinuti na kraju tiskane Upute u pakiranju lijeka, s ciljem da se zdravstvenim djelatnicima pruže ostale dodatne znanstvene i praktične informacije o primjeni i uporabi ovog radiofarmaceutika.
The complete Summary of Product Characteristics (SmPC) of Cuprymina is provided as a separate document in the product pack, with the objective to provide healthcare professionals with other additional scientific and practical information about the use of this product.
Cjeloviti Sažetak opisa svojstava za Cupryminu dostupan je kao zaseban dokument u pakovanju lijeka, s ciljem da zdravstvenim djelatnicima pruži druge dodatne znanstvene i praktične informacije o korištenju ovog lijeka.
The complete Summary of Product Characteristics (SmPC) of Lumark is provided as a separate document in the pack of the medicinal product, with the objective to provide healthcare professionals with other additional scientific and practical information about the use of this product.
Potpun Sažetak opisa svojstava lijeka za Lumark priložen je kao zaseban dokument u pakiranju medicinskog proizvoda, s ciljem pružanja dodatnih znanstvenih i praktičnih informacija zdravstvenim djelatnicima o uporabi ovog proizvoda.
The complex dissociates on uptake from the gastro-intestinal tract and the complex itself does not enter the systemic circulation.
Kompleks je pri unosu odvojen od probavnog trakta i sam po sebi ne ulazi u sustavnu cirkulaciju.
The complex is designed to provide, in a controlled way, utilisable iron for uptake across the intestinal wall and transfer to the iron transport and storage proteins in the body (transferrin and ferritin, respectively).
Kompleks je osmišljen radi osiguravanja, na kontroliran način, željeza upotrebljivog za unos preko crijevnog zida i prijenos željeza do bjelančevina za prijenos i pohranu željeza u tijelu (transferina odnosno feritina).
The complexing agent and other reagents should be added to the vial with Lutetium (177Lu) chloride.
U bočicu s lutecijevim (177Lu) kloridom potrebno je dodati agens za stvaranje kompleksa i ostale reagense.
The complexing agent and other reagents should be added to the vial with Lutetium (177Lu)-chloride.
U bočicu s lutecijevim (177Lu) kloridom potrebno je dodati agens za stvaranje kompleksa i ostale reagense.
the compliance.
kontracepcije.
The composite endpoint of adjudicated cardiovascular and cerebrovascular (CCV) events [acute coronary syndrome (ACS), transient ischaemic attack (with imaging evidence of infarction), stroke or CCV death], was similar for vildagliptin versus combined active and placebo comparators [Mantel– Haenszel risk ratio 0.84 (95% confidence interval 0.63 1.12)].
Kompozitna mjera ishoda utvrđenih kardivaskularnih i cerebrovaskularnih (KCV) događaja [akutni koronarni sindrom (AKS), prolazni ishemijski napad (s dokazom infarkta na snimci), moždani udar ili KCV smrt], bila je slična za vildagliptin u usporedbi s kombiniranim aktivnim i placebo komparatorima [omjer rizika po Mantel–Haenszelovj metodi 0,84 (95% interval pouzdanosti 0,63-1,12)].
The composite endpoint of adjudicated cardiovascular and cerebrovascular (CCV) events [acute coronary syndrome (ACS), transient ischaemic attack (with imaging evidence of infarction), stroke or CCV death], was similar for vildagliptin versus combined active and placebo comparators [Mantel– Haenszel risk ratio 0.84 (95% confidence interval 0.63-1.12)].
Kompozitna mjera ishoda utvrđenih kardivaskularnih i cerebrovaskularnih (KCV) događaja [akutni koronarni sindrom (AKS), prolazni ishemijski napad (s dokazom infarkta na snimci), moždani udar ili KCV smrt], bila je slična za vildagliptin u usporedbi s kombiniranim aktivnim i placebo komparatorima [omjer rizika po Mantel–Haenszelovj metodi 0,84 (95% interval pouzdanosti 0,63-1,12)].
The composition of Raplixa per gram powder is provided in Table 1.
Sastav lijeka Raplixa po gramu praška nalazi se u tablici 1.
The compound is absorbed rapidly into the target tissue for SRD.
Proizvod se brzo absorbira u ciljano tkivo za SRD.
The compound selectively inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukaemic cells from Philadelphia chromosome positive CML and acute lymphoblastic leukaemia (ALL) patients.
Supstancija selektivno inhibira proliferaciju te inducira apoptozu u Bcr- Abl pozitivnim staničnim linijama, kao i u svježim leukemijskim stanicama osoba koje boluju od kronične mijeloične leukemije (KML) s pozitivnim Philadelphia kromosomom i od akutne limfoblastične leukemije (ALL).
The compound selectively inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukaemic cells from Philadelphia chromosome positive CML and ALL patients.
Supstancija selektivno inhibira proliferaciju te inducira apoptozu u Bcr-Abl pozitivnim staničnim linijama, kao i u svježim leukemijskim stanicama osoba s Ph+KML-om i ALL- om.
The concentrate and solvent vials must be used immediately.
Bočice s koncentratom i otapalom moraju se primijeniti odmah.
The concentrate for solution for infusion (or sterile concentrate) is a clear to slightly opalescent and colourless to slightly yellow solution in a glass vial with a rubber stopper.
Koncentrat za otopinu za infuziju (ili sterilni koncentrat) je bistra do blago opalescentna te bezbojna do blijedo žuta otopina u staklenoj bočici s gumenim čepom.
The concentrate for solution for infusion has to be diluted with sodium chloride 9 mg/ml (0.9%) solution for infusion using aseptic technique.
Koncentrat za otopinu za infuziju mora biti aseptičkom tehnikom razrijeđen s 0,9% otopinom natrijeva klorida (9 mg/ml) za infuziju.
The concentrate for solution for infusion has to be diluted with sodium chloride 9 mg/ml (0.9%) solution for infusion using aseptic technique.
Koncentrat za otopinu za infuziju mora se razrijediti s 0,9% otopinom natrijeva klorida za infuziju (9 mg/ml) aseptičkim postupkom.
The concentrate is a clear colourless to pale yellow solution.
Koncentrat je bistra, bezbojna do blijedožuta otopina.
The concentrate is a clear pale yellow to brownish-yellow solution.
Koncentrat je blijedo žuta do smeđežuta otopina.
The concentrate is a clear yellow to brownish-yellow oily solution.
Koncentrat je bistra, žuta do smećkastožuta uljna otopina.
The concentrate is a clear, colourless solution, pH 4.5 – 7.0
Koncentrat je bistra, bezbojna otopina, pH 4,5 – 7,0
The concentrate is clear to slightly hazy opalescent, colourless to slightly yellow.
Koncentrat je bistar do blago zamućen, opalescentan, bezbojan do blago žut.
The concentrate is pale yellow in colour and contains 1 mg per ml of topotecan.
Koncentrat je blijedo žute boje i sadrži 1 mg po ml topotekana.
The concentrate is supplied in a clear and colourless glass vial with a rubber stopper and a plastic flip-off cap.
Koncentrat se isporučuje u prozirnoj i bezbojnoj staklenoj bočici sa gumenim čepom i plastičnim "flip-off" zatvaračem.
The concentrate should then be diluted further in the remaining Savene diluent.
Nakon toga koncentrat treba dodatno razrijediti u preostalom otapalu lijeka Savene.
The concentrate vial (fill: 73.2 mg of cabazitaxel/1.83 ml) and the solvent vial (5.67 ml) contain an overfill to compensate for liquid loss during preparation.
Bočica s koncentratom (punjenje: 73,2 mg kabazitaksela/1,83 ml) i bočica s otapalom (punjenje: 5,67 ml) sadrže dodatnu količinu punjenja kako bi se nadoknadio gubitak tekućine tijekom pripreme.
The concentrate-diluent mixture may only be administered in sodium chloride 9 mg/ml (0.9%) solution for injection.
Mješavina koncentrata i otapala može se primijeniti samo u otopini za injekciju natrijevog klorida 9 mg/ml (0,9%).
The concentrate-diluent mixture should be inspected visually for particulate matter and discolouration.
Mješavinu koncentrata i otapala prije primjene treba vizualno provjeriti na prisutnost čestica ili promjenu boje.
The concentrate-diluent mixture should be inspected visually for particulate matter and discolouration.
Mješavinu koncentrata i otapala treba vizualno provjeriti na prisutnost čestica ili promjenu boje.
The concentration is 20.9 mg/ml (i.e.
Koncentracija je 20,9 mg/ml (tj.
The concentration is 30 micrograms per ml.
Koncentracija je 30 mikrograma po ml.
The concentration of dexrazoxane following reconstitution with 25 ml Savene diluent is 20 mg/ml.
Koncentracija deksrazoksana nakon pripreme s 25 ml otapala lijeka Savene je 20 mg/ml.
The concentration of drug necessary to effect viral replication by 50% (EC50) or 50% inhibitory concentration (IC50) varied according to virus and host cell type.
Koncentracija lijeka potrebna za učinak na virusnu replikaciju za 50% (EC50) ili 50% inhibitornu koncentraciju (IC50) ovisio je o vrsti virusa i stanica.
The concentration of drug necessary to effect viral replication by 50% (IC50 - half maximal inhibitory concentration) varied according to virus and host cell type.
Koncentracija lijeka potrebna da bi se virusna replikacija smanjila za 50% (IC50 - pola maksimalne inhibicijske koncentracije) varirala je ovisno o vrsti virusa i stanice domaćina.
The concentration of ibandronic acid in the solution for injection is 1 mg per ml.
Koncentracija ibandronatne kiseline u otopini za injekciju je 1 mg u ml.
The concentration of sevoflurane necessary to maintain anaesthesia is much less than that required for induction.
Koncentracija sevoflurana neophodna da bi se održala anestezija manja je od one koja je potrebna za uvođenje u anesteziju.
The concentration of these co-administered medicinal products with a narrow therapeutic index or their other pharmacodynamic markers should be monitored when concomitant use with eluxadoline is initiated or discontinued.
Kada se započinje ili prekida istodobna primjena s eluksadolinom, treba nadzirati koncentraciju navedenih istodobno primijenjenih lijekova uskog terapijskog indeksa ili njihovih drugih farmakodinamičkih markera.
the concentration of these medicines.
koncentracije tih lijekova.
The concentration-dependent non-linear clearance plays a major role at low tocilizumab concentrations.
Nelinearni klirens ovisan o koncentraciji igra glavnu ulogu pri niskim koncentracijama tocilizumaba.
The concentration-time profile following intravenous administration is well described by a two- compartment model.
Profil koncentracija-vrijeme nakon intravenske primjene dobro je opisan dvokomponentnim modelom.
The concentrations in the hair coat of fipronil, fipronil sulfone and (S)-methoprene decrease with time but remain detectable for at least 42 days after dosing.
Koncentracije fipronila, fipronil sulfona i (S)-metoprena padaju s vremenom, ali se mogu dokazati najmanje 42 dana nakon primjene.
The concentrations of fipronil, fipronil sulfone, amitraz and S-methoprene in the haircoat then decrease with time and are detectable for at least 58 days after dosing.
Koncentracije fipronila, fipronil sulfona, amitraza i S-metoprena u dlaci tada s vremenom opadaju i dokazive su najmanje 58 dana nakon primjene .
The concentrations of regorafenib and its major pharmacologically active metabolites (M-2 and M-5) were highest when given after a low-fat (light) breakfast as compared to either a high-fat breakfast or fasting condition.
Koncentracije regorafeniba i njegovih glavnih farmakološki aktivnih metabolita (M-2 i M-5) bile su najviše kad se regorafenib davao nakon doručka s niskim udjelom masti (laganog), u usporedbi kad se davao nakon doručka bogatog mastima ili natašte.
The concentrations of the abnormal bile acid metabolites synthesised in 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency (3β, 7α-dihydroxy- and
Potrebno je utvrditi koncentracije abnormalnih metabolita žučne kiseline sintetiziranih u deficijenciji 3β-hidroksi-Δ5-C27-steroid oksidoreduktaze (3β, 7α-dihidroksi- i
The concentrations of the abnormal bile acid metabolites synthesised subesquently should be determined.
Treba utvrditi koncentracije abnormalnih metabolita žučne kiseline koji se naknadno sintetiziraju.
The concentrations of this glucuronide are approximately 10-fold higher than those of unchanged bazedoxifene in plasma.
Koncentracija ovog glukuronida je otprilike 10 puta veća od doze nepromijenjenog bazedoksifena u plazmi.
The concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.5).
Ne preporučuje se istodobna primjena klopidogrela i drugih oralnih antikoagulanasa, jer to može pojačati intenzitet krvarenja (vidjeti dio 4.5.).
The concomitant administration of CRESEMBA and etravirine is contraindicated.
Istovremena primjena lijeka CRESEMBA i etravirina je kontraindicirana.
The concomitant administration of CRESEMBA and St John‟s wort is contraindicated.
Istodobna primjena lijeka CRESEMBA i gospine trave je kontraindicirana.
The concomitant administration of CRESEMBA and St John‟s wort is contraindicated.
Istovremena primjena lijeka CRESEMBA i gospine trave je kontraindicirana.
The concomitant administration of Nevirapine Teva with NNRTIs is not recommended (see section 4.4).
Istodobna primjena Nevirapina Teva s NNRTI-ima se ne preporučuje (vidjeti dio 4.4).
The concomitant administration of other medicinal products that induce CYP3A4 (e.g. phenytoin, carbamazepine, phenobarbital and St. John’s Wort) is likewise likely to reduce exposure to nilotinib to a clinically relevant extent.
Istodobna primjena drugih lijekova koji induciraju CYP3A4 (npr. fenitoin, karbamazepin, fenobarbital i gospina trava) vjerojatno će smanjiti izloženost nilotinibu do klinički značajnih razmjera.
The concomitant administration of pneumococcal conjugate vaccine (PREVENAR) given with hepatitis B vaccine using the 0, 1 and 6 and 0, 1, 2 and 12 month schedules has not been sufficiently studied.
Istodobna primjena pneumokoknog konjugiranog cjepiva (PREVENAR) koje se daje s cjepivom protiv hepatitisa B prema rasporedu 0., 1. i 6. te 0., 1., 2. i 12. mjeseca nije dovoljno ispitana.
The concomitant administration of sirolimus and angiotensin-converting enzyme inhibitors has resulted in angioneurotic oedema-type reactions.
Istodobna primjena sirolimusa i ACE inhibitora u rijetkim je slučajevima rezultirala reakcijama tipa angioneurotskog edema.
The concomitant administration of the product with other anti-hypertensive agents (e.g. calcium channel blockers, β-blockers or diuretics), anaesthetics or sedatives may potentially lead to additive hypotensive effects.
Istovremena primjena ovog veterinarsko-medicinskog proizvoda s drugim antihipertenzivima (primjerice s blokatorima kalcijevih kanala, alfa-blokatorima ili diureticima), anesteticima ili sedativima može uzrokovati dodatne hipotenzivne učinke.
The concomitant administration of Viramune with NNRTIs is not recommended (see section 4.4).
Istodobna primjena Viramunea s NNRTI-ima se ne preporučuje (vidjeti dio 4.4).
The concomitant administration with fusidic acid is contraindicated in dermatological infections. (see section 4.5).
Istodobna primjena s fusidatnom kiselinom je kontraindicirana kod dermatoloških infekcija (vidjeti dio 4.5).
The concomitant administration with quetiapine is contraindicated  (see section 4.5).
Istodobna primjena s  kvetiapinom je kontraindicirana (vidjeti dio 4.5).
The concomitant use of
Istodobna primjena lijekova
The concomitant use of Actelsar HCT with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Actelsar HCT s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of adequate virostatic agents should be considered as standard of hepatitis B re- infection prophylaxis.
Potrebno je razmotriti istodobnu primjenu odgovarajućih virostatika kao standardne profilakse ponovne infekcije hepatitisom B.
The concomitant use of aliskiren with ciclosporin and itraconazole, two highly potent P- glycoprotein (P-gp) inhibitors, and other potent P-gp inhibitors (e.g. quinidine), is contraindicated (see section 4.5).
Kontraindicirana je istodobna primjena aliskirena s ciklosporinom i itrakonazolom, dva visoko potentna inhibitora P-glikoproteina (P-gp), i drugim potentnim P-gp inhibitorima (npr. kinidin) (vidjeti dio 4.5).
The concomitant use of aliskiren with ciclosporin and itraconazole, two highly potent P-gp inhibitors, and other potent P-gp inhibitors (e.g. quinidine), is contraindicated (see section 4.5).
Kontraindicirana je istodobna primjena aliskirena s ciklosporinom i itrakonazolom, dva visoko potentna inhibitora P-glikoproteina (P-gp), i drugim potentnim P-gp inhibitorima (npr. kinidin) (vidjeti dio 4.5).
The concomitant use of amifampridine and substances known to lower the epileptic threshold may lead to an increased risk of seizures.
Istovremena uporaba amifampridina i tvari za koje se zna da snižavaju epileptički prag mogu uzrokovati povećani rizik od napadaja.
The concomitant use of amiodarone was limited through the clinical development of sofosbuvir plus DAAs.
Istodobna primjena amiodarona bila je ograničena tijekom kliničkog razvoja sofobuvira uz antivirotike koji djeluju direktno.
The concomitant use of amlodipine and grapefruit or grapefruit juice is still not recommended in patients as the bioavailability of amlodipine may increase in some and may result in increased hypotensive effects.
Istovremena primjena amlodipina i grejpa ili soka od grejpa se još uvijek ne preporučuje, a kod bolesnika jer se bioraspoloživost amlodipina u nekim slučajevima može povećati te može rezultirati povećanjem hipotenzivnog učinka.
The concomitant use of amlodipine and grapefruit or grapefruit juice is still not recommended in patients as the bioavailability of amlodipine may increase in some and may result in increased hypotensive effects.
Istovremena primjena amlodipina i grejpa ili soka od grejpa se još uvijek ne preporučujea kod bolesnika jer se bioraspoloživost amlodipina u nekim slučajevima može povećati te može rezultirati povećanjem hipotenzivnog učinka.
The concomitant use of antiplatelets ASA or clopidogrel approximately doubles MBE rates with both dabigatran and warfarin.
Istovremena primjena antitrombotika, ASA, ili klopidogrela približno udvostručuje stopu događaja velikih krvarenja i uz dabigatraneteksilat i varfarin.
The concomitant use of antiplatelets ASA or clopidogrel approximately doubles MBE rates with both dabigatran etexilate and warfarin.
Istovremena primjena antitrombotika, ASA, ili klopidogrela približno udvostručuje stope događaja velikih krvarenja i uz dabigatraneteksilat i varfarin.
The concomitant use of apixaban with other strong CYP3A4 and P-gp inducers (e.g., phenytoin, carbamazepine, phenobarbital or St. John’s Wort) may also lead to reduced apixaban plasma concentrations.
Istodobna primjena apiksabana s drugim snažnim induktorima CYP3A4 i P-gp-a (npr. fenitoinom, karbamazepinom, fenobarbitalom ili gospinom travom) također može dovesti do smanjenja koncentracije apiksabana u plazmi.
The concomitant use of Aprovel with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) <60 ml/min/1.73m2) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Aprovel s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Aptivus,
Istodobna primjena Aptivusa s
The concomitant use of Aptivus,
tipranavira/r
The concomitant use of Aptivus, co-
Istodobna primjena Aptivusa s
The concomitant use of Aptivus, co-
Istodobna primjena Aptivusa, s
The concomitant use of Aptivus, co-administered with low dose ritonavir, with alfuzosin is contraindicated.
Istodobna primjena Aptivusa s niskom dozom ritonavira i alfuzosina je kontraindicirana.
The concomitant use of ARICLAIM with selective, reversible MAOIs, like moclobemide, is not recommended (see section 4.4).
Ne preporučuje se istodobna primjena lijeka ARICLAIM sa selektivnim reverzibilnim inhibitorima MAO, poput moklobemida (vidjeti dio 4.4).
The concomitant use of Bosulif with strong CYP3A inducers (including, but not limited to carbamazepine, phenytoin, rifampicin, St. John’s Wort), or moderate CYP3A inducers (including, but not limited to bosentan, efavirenz, etravirine, modafinil, nafcillin) should be avoided, as a decrease in bosutinib plasma concentration will occur.
Nužno je izbjegavati istodobnu primjenu Bosulifa sa snažnim induktorima CYP3A (uključujući, između ostalog karbamazepin, fenitoin, rifampicin, gospinu travu) ili umjerenim induktorima CYP3A (uključujući,između ostalog bosentan, efavirenz, etravirin, modafinil,nafcilin) jer će doći do smanjenja koncentracije bosutiniba u plazmi.
The concomitant use of Bosulif with strong or moderate CYP3A inducers should be avoided as a decrease in bosutinib plasma concentration will occur (see section 4.5).
Nužno je izbjegavati istodobnu primjenu Bosulifa sa snažnim ili umjerenim induktorima CYP3A jer će doći do smanjenja koncentracije bosutiniba u plazmi (vidjeti dio 4.5).
The concomitant use of Bosulif with strong or moderate CYP3A inhibitors should be avoided, as an increase in bosutinib plasma concentration will occur (see section 4.5).
Nužno je izbjegavati istodobnu primjenu Bosulifa sa snažnim ili umjerenim inhibitorima CYP3A jer će doći do porasta koncentracije bosutiniba u plazmi (vidjeti dio 4.5).
The concomitant use of bosutinib with strong CYP3A inhibitors (including, but not limited to itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, nefazodone, mibefradil, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir, boceprevir, telaprevir, grapefruit products including grapefruit juice) or moderate CYP3A inhibitors (including, but not limited to fluconazole, ciprofloxacin, erythromycin, diltiazem, verapamil, amprenavir, atazanavir, darunavir/ritonavir, fosamprenavir, aprepitant, crizotinib, imatinib) should be avoided, as an increase in bosutinib plasma concentration will occur.
Nužno je izbjegavati istodobnu primjenu bosutiniba sa snažniminhibitorima CYP3A (uključujući, između ostalog itrakonazol, ketokonazol, posakonazol, vorikonazol, klaritromicin, telitromicin, nefazodon, mibefradil, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir, sakvinavir, boceprevir, telaprevir, proizvode od grejpa uključujući sok od grejpa) ili umjerenim inhibitorima CYP3A (uključujući, između ostalog flukonazol, ciprofloksacin, eritromicin, diltiazem, verapamil, amprenavir, atazanavir, darunavir/ritonavir, fosamprenavir, aprepitant, krizotinib, imatinib) jer će doći do porasta koncentracije bosutiniba u plazmi.